<DOC>
	<DOCNO>NCT00193349</DOCNO>
	<brief_summary>This study evaluate combination chemotherapy patient extensive stage small cell lung cancer combine potentially useful growth inhibit effect Gleevec .</brief_summary>
	<brief_title>Gleevec Combined With Camptosar Plus Paraplatin Previously Untreated Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Irinotecan + Carboplatin + Imatinib</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>To include study , must meet following criterion : Small cell lung cancer extensive stage disease confirm biopsy Measurable evaluable disease Ability perform activity daily live minimal assistance Adequate bone marrow , liver kidney No active brain metastasis . No previous chemotherapy radiation therapy Give write informed consent . You participate study follow apply : Limited stage disease ( include IA , IB , IIA , IIB , IIIA ) Active brain metastasis Age &lt; 18 year old History prior malignancy within three year Women pregnant lactating . Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>